STING Agonism Enhances Anti-Tumor Immune Responses and Therapeutic Efficacy of PARP Inhibition in BRCA-Associated Breast Cancer

Scientists demonstrated that compared to monotherapies, combined Poly (ADP-ribose) polymerase (PARP) inhibition and STING agonism resulted in increased STING pathway activation, greater cytotoxic T cell recruitment, and enhanced dendritic cell activation in BRCA1-deficient breast cancer models.